Skip to main content
    A

    Adaptive Biotechnologies Corp (ADPT)

    Official site

    HEALTHCARE • DIAGNOSTICS & RESEARCH • NASDAQ

    $27.87
    -1.17 (-4.03%)

    Market Cap: $4.70B

    Last updated: Nov 17, 2026 at 11:04 AM ET

    Adaptive Biotechnologies Corp (ADPT) Financials: Revenue, Profit and Cash Flow

    Updated Nov 4, 2026. Financial statements from company filings, amounts in US dollars.

    Adaptive Biotechnologies reported revenue of $276.98M for the fiscal year ended Dec 31, 2025, up 54.8% from the year before. That year, net income was -$59.46M with a net margin of -21.5%, operating cash flow was -$45.99M and free cash flow was -$48.95M. The quarter ended Sep 30, 2026 had revenue of $83.90M and net income of $2.81M.

    Revenue and Margins

    The operating margin was -20.6% in the fiscal year ended Dec 2025, the highest of the 4 years shown with an operating margin. Over the 8 years to Dec 2025, revenue grew from $15.69M, a compound annual rate of 43.2%.

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Dec 2025$276.98M+54.8%74.2%-20.6%-21.5%
    Dec 2024$178.96M+5.1%59.7%-90.8%-89.2%
    Dec 2023$170.28M-8.1%55.6%-133.3%-132.3%
    Dec 2022$185.31M+20.1%68.7%-108.0%-108.1%
    Dec 2021$154.34M+56.9%68.1%-135.4%-134.3%
    Dec 2020$98.38M+15.6%77.1%-155.3%-148.6%
    Dec 2019$85.07M+52.8%73.8%-92.1%-80.6%
    Dec 2018$55.66M+254.8%64.7%-89.4%-83.4%
    Dec 2017$15.69MN/A0.1%-283.5%-273.0%
    Annual, fiscal years ended Dec 2017 to Dec 2025

    Income Statement

    In the fiscal year ended Dec 2025, the net loss narrowed from the year before. In the quarter ended Sep 2026, net income fell 70.5% from the same quarter a year earlier.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017
    Revenue$276.98M$178.96M$170.28M$185.31M$154.34M$98.38M$85.07M$55.66M$15.69M
    Cost of revenue$71.36M$72.08M$75.55M$57.91M$49.30M$22.53M$22.27M$19.67M$15.68M
    Gross profit$205.62M$106.88M$94.72M$127.40M$105.04M$75.85M$62.80M$35.99M$9.00K
    Research and development$93.77M$102.95M$122.12M$141.76M$142.34M$116.07M$70.70M$39.16M$32.00M
    Operating income-$57.12M-$162.55M-$227.03M-$200.19M-$208.97M-$152.82M-$78.39M-$49.76M-$44.48M
    Net income-$59.46M-$159.59M-$225.30M-$200.37M-$207.30M-$146.23M-$68.61M-$46.45M-$42.83M
    EBITDA-$41.80M-$151.50M-$213.99M-$178.53M-$187.78M-$143.57M-$75.06MN/A-$38.34M
    Fiscal years ended Dec 2017 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Revenue$83.90M$71.55M$70.87M$71.68M$93.97M$58.88M$52.44M$47.46M$46.44M$43.19M$41.87M$45.78M
    Gross profit$63.97M$51.39M$52.17M$53.46M$75.82M$40.88M$35.46M$29.41M$29.77M$23.87M$23.82M$26.17M
    Operating income-$457.00K-$15.77M-$19.21M-$12.77M$10.29M-$25.04M-$29.60M-$33.84M-$32.63M-$47.32M-$48.76M-$71.07M
    Net income$2.81M-$39.94M-$20.02M-$13.58M$9.54M-$25.59M-$29.83M-$33.72M-$32.10M-$46.25M-$47.53M-$69.47M
    Last 12 quarters

    Balance Sheet

    As of Dec 2025, total debt of $131.21M exceeded cash and equivalents by $60.71M.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017
    Total assets$512.74M$539.38M$661.13M$856.62M$923.34M$1.12B$912.30M$332.69M$362.49M
    Current assets$300.19M$283.75M$410.19M$562.15M$402.75M$726.91M$612.69M$180.72M$205.25M
    Cash and equivalents$70.50M$47.92M$65.06M$90.03M$139.06M$123.44M$96.58M$55.03M$85.31M
    Total liabilities$287.74M$336.89M$352.86M$392.52M$319.24M$373.15M$341.26M$29.94M$587.11M
    Short-term debt$4.64M$865.00K$0$9.23M$5.05M$3.53MN/A$0$0
    Long-term debt$126.57M$132.41M$130.66M$125.36MN/AN/AN/A$336.00K$342.00K
    Shareholder equity$218.79M$202.71M$308.40M$464.17M$603.99M$743.27M$571.04M-$258.11M-$224.62M
    Fiscal years ended Dec 2017 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Total assets$683.12M$640.68M$505.94M$512.74M$490.61M$496.64M$510.85M$539.38M$558.51M$584.87M$620.32M$661.13M
    Total liabilities$499.23M$490.02M$281.70M$287.74M$286.36M$317.10M$320.63M$336.89M$334.93M$343.44M$345.56M$352.86M
    Cash and equivalents$75.61M$169.87M$77.58M$70.50M$55.03M$43.16M$50.65M$47.92M$38.08M$59.82M$71.23M$65.06M
    Shareholder equity$176.21M$142.91M$216.34M$218.79M$204.44M$179.72M$190.42M$202.71M$223.77M$241.60M$274.91M$308.40M
    Last 12 quarters

    Cash Flow

    Operating cash flow was negative in the fiscal year ended Dec 2025.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017
    Operating cash flow-$45.99M-$95.21M-$156.32M-$183.94M-$192.73M-$149.68M$205.40M-$32.26M-$34.86M
    Capital expenditures$2.96M$3.66M$10.70M$16.35M$61.75M$18.80M$11.20M$6.30M$2.42M
    Free cash flow-$48.95M-$98.88M-$167.02M-$200.29M-$254.47M-$168.49M$194.20M-$38.56M-$37.28M
    Share repurchasesN/AN/AN/A$0$0$321.00K$4.99M$0$0
    Investing cash flow$37.95M$77.79M$129.65M$2.90M$181.21M-$117.04M-$481.70M$736.00K$36.43M
    Financing cash flow$30.40M$241.00K$2.25M$132.26M$27.15M$293.59M$319.92M$1.25M$50.03M
    Fiscal years ended Dec 2017 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Operating cash flow$9.61M-$6.40M-$9.54M$2.06M-$7.13M-$12.43M-$28.48M-$12.49M-$27.07M-$17.30M-$38.35M-$26.93M
    Capital expenditures$1.93M$1.18M$796.00K$636.00K$409.00K$655.00K$1.26M$80.00K$344.00K$1.73M$1.51M$1.30M
    Free cash flow$7.68M-$7.58M-$10.33M$1.42M-$7.54M-$13.09M-$29.74M-$12.57M-$27.41M-$19.03M-$39.86M-$28.23M
    Last 12 quarters

    Frequently Asked Questions About ADPT

    What is Adaptive Biotechnologies' annual revenue?

    Adaptive Biotechnologies reported revenue of $276.98M for the fiscal year ended Dec 31, 2025.

    How fast is Adaptive Biotechnologies' revenue growing?

    Revenue was up 54.8% for the fiscal year ended Dec 31, 2025 compared with the year before. The compound annual revenue growth rate over 3 years was 14.3%.

    Is Adaptive Biotechnologies profitable?

    No. Adaptive Biotechnologies reported net income of -$59.46M for the fiscal year ended Dec 31, 2025, with a net margin of -21.5%.

    How much free cash flow does ADPT generate?

    For the fiscal year ended Dec 31, 2025, operating cash flow of -$45.99M minus capital expenditures of $2.96M produced free cash flow of -$48.95M.

    How much debt does Adaptive Biotechnologies have?

    The balance sheet dated Dec 31, 2025 reported long-term debt of $126.57M, short-term debt of $4.64M and cash and equivalents of $70.50M.